摘要
目的前瞻性研究含加替沙星的序贯疗法对幽门螺杆菌(Hp)的疗效。方法选折2007～2008年Hp阳性的慢性胃炎或消化性溃疡病人121例,其中62例采用含加替沙星的序贯疗法治疗,59例采用标准PP三I联疗法。结果含加替沙星的序贯疗法治疗组总根除率90.3%,标准PP三I联疗法组总根除率76.3%,两组之间有明显差别(0.01<P<0.05),不良反应无明显差异(P>0.05)。结论含加替沙星的序贯疗法治疗组根除率高,副反应低,值得临床应用推广。
Objective prospective study with gatifloxacin in sequential therapy for Helicobacter pylori （Hp） efficacy. Methods Elections of folding 2007-2008 Hp-positive patients with chronic gastritis or peptic ulcer in 121 cases, of which 62 cases with Gatifloxacin-containing sequential therapy, 59 patients with standard PPI triple therapy. Results Gatifloxacin-containing sequential therapy group was 90.3% eradication rate, standard PPI triple therapy group was 76.3% eradication rate, there are significant differences between the two groups （0.01 P0.05）, no significant difference in adverse reactions （P0.05）. Conclusions Gatifloxacin-containing sequential therapy group the eradication rate, side effects is low, worthy of clinical application and popularization.
出处
《当代医学》
2010年第28期21-22,共2页
Contemporary Medicine
关键词
加替沙星
幽门螺杆菌
根除
Gatifloxacin
Helicobacter pylori
eradicated
